Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (2148)	10/6/1997 9:58:00 AM
From: scaram(o)uche	of 6136

Henry: You asked "if a naive to PI patient begins on a PI other than Viracept, what happens when they switch to Viracept - I assume that 100% are not successful, but is the rate significantly lower than a switch from another PI to Viracept?" Your assumption is correct, but your question (paraphrased) "is the rate of success for a competitor to Viracept switch lower than that for a competitor to Viracept switch?" needs clarification. Your "100% are not successful" also needs clarification. If you mean that "the failure rate is greater than 0%" (as it reads), you are correct. If you mean that "100% fail", we of course can't say that. There have been annecdotal reports of the expected failure that I've seen, and AGPH's old (I haven't looked closely at the issue since I sold) in vitro data indicated that 82/84 variants were 100% resistant to Viracept. There have also been annecdotal reports of success with Viracept after failure on crix. I think everyone questions the durability of such responses, if they are actually backed up by hard data. But, after you clarify your questions, I would ask IR or Dr. Ogden at AGPH for answers, as I'm not up to date. Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next